MarketCap
Facebook
X
Telegram
Tenax Therapeutics Market Cap | TENX
As of October 27, 2026 Tenax Therapeutics has a market cap of $ 64.7 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 1967 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 569 M | 222 M | 1.05 M | 121 K | 20.6 M | 17.1 M | 8.43 M | 1.83 M | 9.03 M | 54.8 M | 102 M | 43.9 M | 6.25 M | 49.3 M | 45.8 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 569 M | 121 K | 76.7 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Caladrius Biosciences
CLBS
|
3.58 M | - | -16.75 % | $ 25.8 M |  USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
5.58 K | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
109 K | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
11.7 M | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
48.3 M | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
1.44 M | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
561 M | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
3.86 M | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
800 K | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
180 M | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
76.3 M | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
4.43 B | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
22.9 M | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
935 K | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
18.1 M | - | 9357.83 % | $ 1.01 B | USA |
 |
Graybug Vision
GRAY
|
1.97 M | - | -11.23 % | $ 9.65 M | USA |
|
Galera Therapeutics
GRTX
|
7.65 M | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
8.91 M | - | 1.35 % | $ 17.8 M |  China |
 |
Hepion Pharmaceuticals
HEPA
|
376 K | - | -18.79 % | $ 39.3 K | USA |
 |
Hoth Therapeutics
HOTH
|
11.2 M | - | - | $ 18.8 M | USA |
 |
IMARA
IMRA
|
225 M | - | 15.96 % | $ 663 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
836 M | - | - | $ 1.45 B |  Britain |
 |
KemPharm
KMPH
|
206 M | - | -0.34 % | $ 200 M | USA |
 |
Kezar Life Sciences
KZR
|
45.4 M | - | - | $ 53.3 M | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
27 M | - | - | $ 63.4 M | USA |
 |
Magenta Therapeutics
MGTA
|
3.61 M | - | -7.74 % | $ 41.6 M | USA |
 |
NovaBay Pharmaceuticals
NBY
|
7.1 M | - | - | $ 11.3 M | USA |
 |
NeuroBo Pharmaceuticals
NRBO
|
20.7 M | - | 0.43 % | $ 12 M | USA |
 |
OncoCyte Corporation
OCX
|
1.94 M | - | 17.22 % | $ 355 K | USA |
 |
Onconova Therapeutics
ONTX
|
1.55 M | - | -0.47 % | $ 21 M | USA |
 |
Opthea Limited
OPT
|
2.11 B | - | - | $ 1.2 B |  Australia |
|
BiomX
PHGE
|
8.56 M | $ 1.85 | 14.2 % | $ 3.02 M |  Israel |
 |
Pieris Pharmaceuticals
PIRS
|
30.3 M | - | -15.58 % | $ 1.22 B |  Germany |
 |
Plus Therapeutics
PSTV
|
22.6 M | - | - | $ 301 M | USA |
 |
Pluristem Therapeutics
PSTI
|
6.53 M | - | -1.9 % | $ 33.3 M | Israel |
 |
Qualigen Therapeutics
QLGN
|
1.23 M | - | 5.59 % | $ 1.16 M | USA |
|
Qilian International Holding Group Limited
QLI
|
68.2 M | - | -6.08 % | $ 184 M | China |
 |
Cassava Sciences
SAVA
|
103 M | - | - | $ 110 M | USA |
 |
Selecta Biosciences
SELB
|
4.5 M | - | -8.69 % | $ 126 M | USA |
 |
Sangamo Therapeutics
SGMO
|
86.9 M | - | - | $ 50.4 M | USA |
 |
Salarius Pharmaceuticals
SLRX
|
253 K | - | - | $ 2.64 M | USA |
 |
Sensei Biotherapeutics
SNSE
|
31.7 M | - | - | $ 17.5 M | USA |
 |
Sonnet BioTherapeutics Holdings
SONN
|
1.13 M | - | - | $ 826 K | USA |
 |
Synthetic Biologics
SYN
|
1.29 M | - | 1.32 % | $ 16.2 M | USA |
 |
Synlogic
SYBX
|
16 M | - | - | $ 7.07 M | USA |
 |
Virios Therapeutics, LLC
VIRI
|
3.99 M | - | 2710.01 % | $ 72.9 M | USA |
 |
Vallon Pharmaceuticals
VLON
|
1.12 K | - | -6.47 % | $ 5.76 M | USA |
 |
Vaxart
VXRT
|
152 M | - | -25.06 % | $ 46.3 M | USA |
 |
XOMA Corporation
XOMA
|
330 M | - | - | $ 485 M | USA |
 |
Repare Therapeutics
RPTX
|
50 M | - | - | $ 112 M |  Canada |